Recombinant adeno-associated virus AAV-Lec as well as preparation method and application thereof

The anti-Aβ antibody is delivered to the central nervous system through the recombinant adeno-associated virus AAV-Lec vector, which solves the problem of low permeability of the blood-brain barrier, significantly reduces Aβ plaque, improves AD symptoms and reduces side effects, and achieves anti-Aβ antibodies Effective targeted therapy.

CN118909979APending Publication Date: 2024-11-08HANGZHOU NORMAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410999352.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing anti-Alzheimer's disease (AD) therapy is low in blood-brain barrier permeability and requires high doses of anti-Aβ antibodies to effectively reduce Aβ plaques. There are side effects such as cerebral edema or bleeding, and it is urgently necessary to have smaller side effects. Effective therapy.

Method used

The recombinant adeno-associated virus AAV-Lec is used as a vector to carry anti-Aβ antibody genes, deliver anti-Aβ antibodies to the central nervous system through the blood-brain barrier, and use signal peptides to guide the secretion of antibodies to the cells, combining flexible linking peptides and lenkanemonium antibody. The fusion protein formed by the Fc segment of the light chain, heavy chain variable region and IgG constant region significantly reduces Aβ plaque formation.

Benefits of technology

The targeted release of anti-Aβ antibodies in the central nervous system was achieved, significantly improved AD pathological symptoms, reduced the occurrence of side effects, especially avoided inflammatory responses, and safety assessment showed that it would not cause cerebral microbleeding or liver inflammation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909979A_ABST
    Figure CN118909979A_ABST
Patent Text Reader

Abstract

The invention discloses a recombinant adeno-associated virus AAV-Lec as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The AAV-Lec is an adeno-associated virus for expressing an anti-Abeta antibody, and the anti-Abeta antibody is formed by a fusion protein consisting of a signal peptide for guiding protein to be secreted to extracellular, a light chain variable region and a heavy chain variable region of a lenkanamazumab connected by a flexible connecting peptide, and an Fc segment of an IgG constant region. The recombinant adeno-associated virus AAV-Lec capable of penetrating through the blood-brain barrier is constructed by using the adeno-associated virus as a carrier, an anti-A beta antibody gene expression cassette is carried, an anti-A beta antibody retains an antigen binding region of a lenkanamazumab, and an N-terminal is fused with a signal peptide and is responsible for guiding protein out of a cell and binding the protein with alpha beta starch protein deposited out of the cell, so that the recombinant adeno-associated virus AAV-Lec can penetrate through the blood-brain barrier, and the recombinant adeno-associated virus AAV-Lec can penetrate through the blood-brain barrier. The formation of A beta plaques is inhibited, and the pathological symptoms of the Alzheimer's disease are remarkably improved. Targeted release and effect of antibody drugs are achieved, and side effects are reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a recombinant adeno-associated virus AAV-Lec and a preparation method and application thereof. Background Art

[0002] The World Health Organization estimates that more than 33 million people currently suffer from Alzheimer's disease (AD), which is the leading cause of dementia. The amyloid cascade theory holds that amyloid-β (Aβ) peptide is the main component of amyloid plaques. The amyloid cascade hypothesis holds that the accumulation of (Aβ) peptides induces Alzheimer's disease (Glenner GG, et al. 1984), followed by tau phosphorylation, neuronal cell death, and ultimately cognitive impairment (Hardy JA, et al. 1992; Frisoni GB, et al. 2022; Sims R, et al. 2020).

[0003] The amyloid cascade hypothesis is strongly supported by genetic studies, as autosomal dominant mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1), and PSEN2 proteins increase Aβ production, leading to familial AD with almost 100% penetrance (Chartier-Harlin MC, et al. 1991; Goate A, et al. 1991; Murrell J et al. 1991; Reitz C, et al. 2023). People with multiple copies of APP (such as trisomy 21) often suffer from early-onset AD (Wiseman FK, et al. 2015; Mumford P, et al. 2022; Rovelet-Lecrux A, et al. 2006). Various transgenic mice expressing mutant human APP and dominant PSEN1 mutants also exhibit pathological features similar to AD (Jankowsky JL, et al. 2004; Oakley H, et al. 2006; Sasaguri H, et al. 2017). Conversely, mutations that lead to reduced Aβ production can reduce the risk of AD (Jonsson T, et al. 2012).

[0004] The amyloid cascade hypothesis holds that if Aβ production can be inhibited or Aβ clearance can be enhanced, the development of AD can be prevented (Gu X, et al. 2024; Neatu M, et al. 2023; Karran E, et al. 2022). Over the past few decades, treatment strategies have focused on inhibiting Aβ production or increasing Aβ clearance. Due to lack of efficacy and toxic side effects, more than a dozen clinical trials aimed at reducing Aβ have repeatedly failed, raising doubts (Panza F, et al. 2019; Zhang Y, et al. 2023). Despite this, two anti-Aβ monoclonal antibody drugs, Aducanumab and Lecanemab, have shown clinical efficacy and were approved by the US Food and Drug Administration in 2021 and 2023, respectively (Sevigny J, et al. 2016; Van Dyck CH, et al. 2023). However, due to the low permeability of the blood-brain barrier, a high dose of 10 mg / kg of anti-Aβ antibody is required to effectively reduce Aβ plaques (Pardridge WM.2020).

[0005] Accumulated evidence shows that anti-Aβ therapy has the potential to improve or even prevent the progression of AD, but these therapies have all been associated with amyloid-related imaging abnormalities (ARIA), with cerebral edema or hemorrhage being the most common adverse reactions (Gu X, et al. 2024; Sevigny J, et al. 2016; Van Dyck CH, et al. 2023; Honig LS, et al. 2023). This side effect may be due to the binding of antibodies to amyloid deposits in blood vessels, triggering an inflammatory response (Taylor X, et al. 2023). Therefore, effective therapies with fewer side effects are urgently needed. Summary of the invention

[0006] The purpose of the present invention is to provide a drug delivery system that can pass anti-Aβ monoclonal antibody drugs through the blood-brain barrier with low side effects, so as to achieve targeted release of anti-Aβ monoclonal antibody drugs in the central nervous system to exert anti-Aβ effects, and to improve the progression of Alzheimer's disease.

[0007] To achieve the above object, the present invention adopts the following technical solution:

[0008] The present invention provides a recombinant adeno-associated virus AAV-Lec, wherein the AAV-Lec is an adeno-associated virus expressing an anti-Aβ antibody, wherein the anti-Aβ antibody is formed by a fusion protein consisting of a signal peptide for guiding protein secretion to the extracellular space, a lencanerumab light chain variable region and a heavy chain variable region connected by a flexible connecting peptide, and an IgG constant region Fc segment.

[0009] The present invention utilizes adeno-associated virus (AAV) with enhanced central nervous system delivery capability as a delivery vector for anti-Aβ antibody encoding genes to construct a recombinant adeno-associated virus AAV-Lec. Animal experiments have shown that the recombinant virus can successfully deliver genes expressing anti-Aβ antibodies to the brains of Alzheimer's disease (AD) model animals, and express anti-Aβ antibodies in the brain, significantly reducing the formation of Aβ plaques, and thus significantly improving AD pathological symptoms. Therefore, the recombinant adeno-associated virus AAV-Lec provided by the present invention can be used to prepare drugs for the treatment and prevention of Alzheimer's disease.

[0010] In the present invention, the anti-Aβ antibody is obtained by modifying the structure of the anti-Aβ monoclonal antibody drug Lecanemab. The amino acid sequence of the anti-Aβ antibody is composed of a signal peptide, a light chain variable region of Lecanemab, a flexible connecting peptide, a heavy chain variable region of Lecanemab, and an IgG constant region Fc segment from the N-terminus to the C-terminus.

[0011] Specifically, the present invention retains the variable regions of the light chain and heavy chain in Lencanermab, and retains its antigen binding region. A flexible connecting peptide is used to connect the two, and the linker can be bent to ensure the formation of the antibody structure. The C-terminus of the heavy chain variable region is fused to the IgG constant region Fc segment, and the fusion protein is expressed and assembled to form an antibody structure. Since αβ amyloid protein is mainly deposited outside the cell, the present invention fuses a signal peptide to the N-terminus of the antibody protein to guide the antibody to be secreted outside the cell.

[0012] Preferably, the amino acid sequence of the signal peptide is shown in SEQ ID NO. 1. The signal peptide used in the present invention is not limited thereto, and other signal peptides that can guide protein secretion to the extracellular space may also be used.

[0013] Preferably, the amino acid sequences of the light chain variable region and the heavy chain variable region of lencanezumab are shown as SEQ ID NO.2 and SEQ ID NO.3, respectively.

[0014] Preferably, the amino acid sequence of the flexible connecting peptide is shown in SEQ ID NO. 4. The flexible connecting peptide may be used in the present invention but is not limited thereto.

[0015] Preferably, the amino acid sequence of the IgG constant region Fc segment is shown in SEQ ID NO. 5. The present invention can use the IgG constant region Fc segment but is not limited thereto, and can also use the Fc segment of lencanezumab.

[0016] The recombinant adeno-associated virus AAV-Lec provided by the present invention contains an anti-Aβ antibody gene expression frame. When constructing the gene expression frame, the codon optimization of the anti-Aβ antibody coding gene can be performed according to the codon preference of the host cell.

[0017] The coding gene of the anti-Aβ antibody consists of a start codon, a signal peptide coding sequence, a light chain variable region coding sequence, a flexible connecting peptide coding sequence, a heavy chain variable region coding sequence, an IgG constant region Fc segment coding sequence, and a stop codon in sequence.

[0018] Preferably, the coding sequences of the signal peptide, light chain variable region, flexible connecting peptide, heavy chain variable region, and IgG constant region Fc segment are shown as SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, and SEQ ID NO.10, respectively.

[0019] Preferably, the promoter in the anti-Aβ antibody gene expression frame adopts EF1A promoter.

[0020] The present invention also provides a method for preparing the recombinant adeno-associated virus AAV-Lec using an adeno-associated virus vector system plasmid, comprising: transfecting the adeno-associated virus vector system plasmid into 293T cells, collecting the cell culture supernatant on time after culturing, concentrating it, mixing it with the cell lysis supernatant, purifying it, and desalting it to obtain the recombinant adeno-associated virus AAV-Lec; the adeno-associated virus vector system plasmid comprises a transfer plasmid containing an anti-Aβ antibody gene expression frame, an expression plasmid encoding replication and capsid proteins, and a helper plasmid Helper, and the three are transfected at a ratio of 1:1:4. During transfection, the ratio of the plasmid to polyethyleneimine (PEI) is 1:3.

[0021] Preferably, the adeno-associated virus serotype is selected from: AAV9, AAV-PHP.A, AAV-PHP.B, AAV.PHP.eB, AAV.BI-hTFR1, AAV-AS. These serotypes of AAV viruses have the ability to efficiently penetrate the blood-brain barrier and enter the central nervous system.

[0022] The present invention also provides the use of the recombinant adeno-associated virus AAV-Lec in the preparation of a drug for treating and preventing Alzheimer's disease, wherein the drug is injected intravenously through the blood-brain barrier to express anti-Aβ antibodies in the central nervous system. Animal experiments have shown that the recombinant adeno-associated virus AAV-Lec provided by the present invention can pass through the blood-brain barrier to deliver anti-Aβ antibody genes to the central nervous system and effectively express anti-Aβ antibodies in brain tissue. The expression of Aβ antibodies in brain neurons can significantly reduce the formation of Aβ plaques, and also reduce the activation of microglia and astrocytes, significantly improving the cognitive function of AD model animals.

[0023] The present invention also provides the use of the recombinant adeno-associated virus AAV-Lec in the preparation of a drug for alleviating abnormal lipid metabolism caused by Alzheimer's disease. The present invention found through transcriptome sequencing analysis that compared with the control group, genes related to lipid metabolism in the liver of AD model animals were significantly downregulated after treatment with the recombinant adeno-associated virus AAV-Lec, indicating that AAV-Lec-mediated immunotherapy plays a role in alleviating abnormal lipid metabolism.

[0024] The results of the safety evaluation experiment showed that the immunotherapy mediated by the recombinant adeno-associated virus AAV-Lec provided by the present invention does not cause brain microbleeds or liver inflammation, indicating that the drug provided by the present invention has few side effects.

[0025] Another object of the present invention is to provide a recombinant adeno-associated virus AAV-Lec preparation, which comprises an effective dose of the recombinant adeno-associated virus AAV-Lec and a pharmaceutically acceptable carrier.

[0026] The preparation is prepared by adding a recombinant adeno-associated virus AAV-Lec as the main active ingredient and a pharmaceutically acceptable carrier, and can be prepared according to the preparation preparation method recorded in pharmacy. The preparation form can be, but is not limited to, an injection preparation. The specific dosage is adjusted according to the type of disease, the severity of the disease, the age and the purpose of administration.

[0027] Preferably, the virus titer in the preparation is 1.0×10 12 -1.0×10 13 vg / mL.

[0028] Terminology Note:

[0029] The term "comprising" is an open expression, that is, it includes the contents specified in the present invention but does not exclude other contents.

[0030] The term "treating" refers in some embodiments to ameliorating a disease or condition (i.e., slowing or preventing or alleviating the development of a disease or at least one clinical symptom thereof). In other embodiments, it refers to alleviating or improving at least one physical parameter, including physical parameters that may not be perceived by the subject. In other embodiments, it refers to regulating a disease or condition physically (e.g., stabilizing a perceptible symptom) or physiologically (e.g., stabilizing a physical parameter), or both. In other embodiments, it refers to preventing or delaying the onset, onset, or exacerbation of a disease or condition.

[0031] The term "effective dose" refers to an amount of a compound that is sufficient to be effective in treating a disease when administered to a subject. The effective dose may vary with the severity of the disease, and the physical condition, age, weight, sex, etc. of the subject to be treated.

[0032] The term "pharmaceutically acceptable carrier" refers to any preparation or carrier medium that can deliver an effective dose of the active substance of the present invention without interfering with the biological activity of the active substance and having no toxic side effects on the host or subject.

[0033] The present invention has the following beneficial effects:

[0034] The present invention uses adeno-associated virus (AAV) as a vector to construct a recombinant adeno-associated virus AAV-Lec that can cross the blood-brain barrier. The recombinant virus carries an anti-Aβ antibody gene expression frame, and after penetrating the blood-brain barrier, the anti-Aβ antibody is expressed in the central nervous system. The anti-Aβ antibody retains the antigen binding region of lencanerizumab and can play a role in binding to αβ amyloid protein; the antibody protein N-terminal fusion signal peptide is responsible for guiding the protein to the outside of the cell, binding to the αβ amyloid protein deposited outside the cell, inhibiting the formation of Aβ plaques, and significantly improving the pathological symptoms of Alzheimer's disease. The AAV-Lec provided by the present invention can achieve the targeted release and action of the drug, avoid the problem of easy inflammatory response in direct antibody administration, and reduce the side effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 Schematic diagram of the structure and sequence composition of the protein encoded by the anti-Aβ antibody gene Lec, where A represents the protein structure and B represents the sequence composition.

[0036] Figure 2 The figure shows the results of Western blot analysis of proteins transiently expressed by PAAV-EF1A-Lec vector.

[0037] Figure 3 ELISA for AAV-Lec antibody with Aβ40 and Aβ42.

[0038] Figure 4 Schematic diagram of the effects of AAV-Lec-mediated immunotherapy.

[0039] Figure 5 These are the results of Flag tag detection in brain tissue of APP / PS1 mice after AAV-Lec treatment. The results show that AAV-Lec can pass through the blood-brain barrier and be expressed in the central nervous system.

[0040] Figure 6 Experimental roadmap for AAV-Lec treatment of APP / PS1 mice.

[0041] Figure 7 These are the results of Thioflavin-S staining of brain tissues of male and female APP / PS1 mice after treatment with AAV-Lec. The results show that AAV-Lec can reduce Aβ accumulation in the cerebral cortex and hippocampus of APP / PS mice.

[0042] Figure 8 for Figure 7 Statistical results of the total area and total number of Aβ plaques in the APP / PS1 AD mouse group, where A is the plaque size per unit area in male mice; B is the plaque size per unit area in female mice.

[0043] Fig. 9 for Figure 7 The quantitative statistical results of different Aβ plaque areas, where A is the male mouse group; B is the female mouse group.

[0044] Fig.10 The results of the water maze test of APP / PS1 mice after AAV-Lec treatment, where A represents the time for the male mouse group to find the platform during the hidden platform period, and B and C represent the number of laps across the platform and the time the male mouse group stayed in the platform quadrant during the platform-free exploration period, respectively. Similarly, D, E, and F are the statistical results of the water maze of the female mouse group. The results showed that in the 5-day experiment of the hidden platform period, the latency of APP / PS1 male and female mice to reach the target box was shorter after AAV-Lec treatment. At the same time, in the experiment of the platform-free exploration period, the mice treated with AAV-Lec stayed in the target box longer and crossed the probe more times in the exploration test. The results showed that AAV-Lec treatment can improve the learning and cognitive ability of APP / PS mice.

[0045] Fig.11 Microglia (IBA1) in APP / PS1 mice treated with AAV-Lec + ) and astrocytes (GFAP + ) activation, where A is the microglia (IBA1 + ) Antibody markers, astrocytes (GFAP + ) antibody markers and Aβ amyloid protein antibody co-stained immunofluorescence results; B is the statistical results of Aβ amyloid protein antibody immunofluorescence; C is astrocytes (GFAP + ) antibody immunofluorescence results, D is microglia (IBA1 + ) Statistical results of antibody immunofluorescence. The results showed that AAV-Lec could reduce the activation of microglia and astrocytes in APP / PS1 mice.

[0046] Fig.12The results of the changes in the number and total area of ​​Aβ plaques in the brain tissue of 5×FAD mice after AAV-Lec treatment, where A is the Thioflavin-S staining result; B is the statistical result of the total area of ​​Aβ plaques per unit area; C is the number of statistical results under different Aβ plaque areas. The results show that AAV-Lec can reduce the accumulation of Aβ in 5×FAD mice.

[0047] Fig.13 These are the results of Prussian blue staining of brain tissue in the AAV-Lec treatment group and the AAV-EGFP control group. The results show that AAV-Lec treatment does not lead to cerebral amyloid angiopathy and microbleeding in brain tissue.

[0048] Fig.14 These are the results of HE staining of liver tissues in the AAV-Lec treatment group and the AAV-EGFP control group. The results showed that there were no obvious pathological changes after AAV-Lec treatment.

[0049] Fig.15 Volcano plot analysis of significantly up-regulated and down-regulated genes in liver RNA-seq.

[0050] Fig.16 Heat map analysis of 12 lipid metabolism-related genes in liver RNA-seq.

[0051] Fig.17 KEGG pathway enrichment analysis of the top 10 enriched genes in liver RNA-seq.

[0052] Fig.18 These are the q-PCR results of lipid metabolism-related genes in the liver and brain tissues of APP / PS1 mice in the AAV-EGFP control group and the AAV-Lec treatment group, where A is the liver tissue and B is the brain tissue. DETAILED DESCRIPTION

[0053] The present invention will be further described below in conjunction with specific embodiments. The following embodiments are only used to illustrate the present invention and are not intended to limit the scope of application of the present invention. Without departing from the spirit and essence of the present invention, modifications or replacements made to the inventive method, steps or conditions all belong to the scope of the present invention.

[0054] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.

[0055] Example 1: Construction and verification of AAV-Lec

[0056] 1. Synthesis of anti-Aβ antibody gene

[0057] The amino acid sequence of the protein encoded by the anti-Aβ antibody gene Lec is shown in SEQ ID NO.11, and the sequence composition diagram is shown in Figure 1 As shown, it is specifically composed of ① signal peptide, ② light chain variable region, ③ Linker, ④ heavy chain variable region, ⑤ hIgG1Fc, and ⑥ Flag. The amino acid sequences of ①-⑤ are shown in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.4, SEQ ID NO.3, and SEQ ID NO.5, respectively, and the amino acid sequence of Flag is: DYKDDDDK.

[0058] The encoding gene is shown in SEQ ID NO.12, wherein 4-57 is a signal peptide encoding sequence, 58-393 is a light chain variable region encoding sequence, 393-462 is a linker, 463-834 is a heavy chain variable region encoding sequence, 835-1824 is a hIgG1Fc encoding sequence, and 1825-1848 is a Flag encoding sequence.

[0059] First, the signal peptide, light chain variable region, linker, and heavy chain variable region of the anti-Aβ antibody Lecanemab were fused to form Lec-scFv by de novo synthesis. The primers used are shown in Table 1. The primers Lec-scFv-1 to Lec-scFv-20 were synthesized by PCR. Then, Lec-scFv, human IgG1 constant region hIgG1Fc, and Flag were cloned and fused to obtain Lec.

[0060] The specific construction steps are as follows:

[0061] (1) Obtain fragment 1 (①+②+③+④)

[0062] Take 1 μL of each of the primers Lec-scfv-1 to Lec-scfv-19 with a concentration of 10 μM / L, shake and mix evenly, mark them as Lec-scFv fragments, and then perform the following PCR steps.

[0063] Preparation of PCR reaction solution: the reaction system (30 μL) consists of: PAAV-EF1-Lec-F1 1 μL, Lec-scFv-20 1 μL, Lec-scFv 1 μL, 5× PrimeSTAR GXL buffer 6 μL, PrimeSTARGXL DNA Polymerase 1 μL, 2.5 mM dNTP Mixture 2.5 μL, and ddH2O to make up 30 μL.

[0064] PCR reaction conditions: (1) 98°C for 30 seconds; (2) 98°C for 10 seconds, 55°C or 60°C for 15 seconds, 68°C for 1 minute / kb, 30 cycles; (3) 68°C for 10 minutes; (4) stored at 16°C.

[0065] The PCR product was recovered using a DNA Clean-up Kit (Kangwei Century) to obtain the de novo synthesized target fragment 1 (①+②+③+④).

[0066] (2) Obtain target fragment 2 (⑤+⑥)

[0067] Using pRVL-5 plasmid (purchased from Addgene) as a template, PCR was performed with primers PAAV-EF1-Lec-F2 and PAAV-EF1-Lec-R2 to obtain the human hIgG1 constant region hIgG1Fc and FLAG fusion fragment.

[0068] Preparation of PCR reaction solution: the reaction system (30 μL) consists of: PAAV-EF1-Lec-F2 1 μL, PAAV-EF1-Lec-R2 1 μL, pRVL-5 plasmid 1 ng, 5× PrimeSTAR GXL buffer 6 μL, PrimeSTAR GXL DNA Polymerase 1 μL, 2.5 mM dNTP Mixture 2.5 μL, and ddH2O to make up 30 μL.

[0069] PCR reaction conditions: (1) 98°C for 30 seconds; (2) 98°C for 10 seconds, 55°C or 60°C for 15 seconds, 68°C for 1 minute / kb, 30 cycles; (3) 68°C for 10 minutes; (4) stored at 16°C.

[0070] The PCR product was recovered using a DNA Clean-up Kit (Kangwei Century) to obtain the target fragment 2 (⑤+⑥).

[0071] (3) Obtain the linear target gene Lec (①+②+③+④+⑤+⑥)

[0072] Primers PAAV-EF1-Lec-F1 and PAAV-EF1-Lec-R2 were used to perform PCR to clone and fuse target fragment 1 and target fragment 2.

[0073] Preparation of PCR reaction solution: the reaction system (30 μL) consists of: PAAV-EF1-Lec-F1 1 μL, PAAV-EF1-Lec-R2 1 μL, target fragment 1 1 ng, target fragment 2 1 ng, 5× PrimeSTAR GXL buffer 6 μL, PrimeSTAR GXL DNA Polymerase 1 μL, 2.5 mM dNTP Mixture 2.5 μL, and ddH2O to make up 30 μL.

[0074] PCR reaction conditions: (1) 98°C for 30 seconds; (2) 98°C for 10 seconds, 55°C or 60°C for 15 seconds, 68°C for 1 minute / kb, 30 cycles; (3) 68°C for 10 minutes; (4) stored at 16°C.

[0075] The PCR product was recovered using a DNA Clean-up Kit (Kangwei Century) to obtain the linear target gene Lec (①+②+③+④+⑤+⑥).

[0076] Table 1. Primers used for de novo synthesis of target genes

[0077]

[0078]

[0079] 2. Preparation of vector DNA fragments.

[0080] The PAAV-EF1A-EGFP vector (purchased from Yunzhou Biotechnology Co., Ltd.) was digested with NcoI and EcoRI restriction endonucleases overnight at 37° C. The digested product was treated in an 80° C. metal bath for 10 minutes to inactivate the enzyme activity, and finally a PAAV-EF1A-NcoI-EcoRI double digested product was obtained.

[0081] 3. Recombination and scarless cloning.

[0082] In a 10 μL reaction system, add 50 ng of PAAV-EF1A-NcoI-EcoRI double-digestion product, the linear target gene Lec, 1 μL of 10×T4 DNA polymerase buffer and 0.33 μL of T4 DNA polymerase, and make up the rest to 10 μL with water.

[0083] The reaction conditions were: 25°C for 3 min, then 75°C for 5 min, slowly cooling to 50°C, and 50°C for 10 min.

[0084] Finally, the product was transformed into competent cells, identified by picking bacteria, and sequenced to obtain the PAAV-EF1A-Lec vector, which is an AAV vector, in which the promoter controlling Lec expression is the broad-spectrum EF1A promoter.

[0085] 4. Verification of AAV-Lec

[0086] In order to verify the specificity of the Aβ antibody expressed by the PAAV-EF1A-Lec vector, this example detected the transient expression by transfecting HEK293T cells.

[0087] The night before, plate 293T cells in a 6-well plate. The plated volume should be about 70-80% during transfection. Prepare two EP tubes, add 125μL DMEM culture medium and the plasmid to be transfected (plasmid 2.5ug / well), marked as liquid A; add 95μL DMEM culture medium and 30μL PEI transfection reagent to the other tube, marked as liquid B. Mix liquid A and liquid B and shake on a vortex mixer, cover and let stand for 25 minutes. Then add the AB mixture to the 293T cells, and replace the cell culture medium after 6-8 hours. 36 hours after transfection, collect the cells in the 6-well plate.

[0088] After lysing for 30 min with 200 μL of Western cell lysis buffer, Western blot analysis confirmed that the molecular weight of the expressed antibody was in line with expectations, with a molecular weight of about 68 KD, and a band around 70 KD. Figure 2 .

[0089] The specific binding of AAV-Lec protein to Aβ40 and Aβ42 was verified by enzyme-linked immunosorbent assay. The results showed that AAV-Lec had a high affinity for both Aβ40 and Aβ42. Figure 3 Example 2: AAV-Lec reduces Aβ accumulation and improves cognitive impairment in APP / PS1 mice

[0090] 1. In order to cross the blood-brain barrier and express Lec in the central nervous system, we used the three-plasmid packaging system of adeno-associated virus (AAV) to produce recombinant AAV virus in vitro.

[0091] The transfer plasmid, expression plasmid (Rep-Cap plasmid), and helper plasmid (Helper plasmid) in the three-plasmid packaging system were co-transfected into 150mm HEK293 cells at a ratio of 1:1:4, with a total plasmid of 10μg and a plasmid to PEI ratio of 1:3. Virus particles exist in both packaging cells and culture supernatants, so we collected the cell supernatant after 72 hours of transfection and added fresh culture medium for further culture, and collected the cell culture supernatant and cell lysis supernatant after 120 hours of transfection. The cell culture supernatant collected twice was combined, and then 40% PEG8000 was added to a final concentration of 8% to concentrate the cell supernatant. The concentrated virus and cell lysis supernatant were mixed and added to an ultracentrifuge tube and centrifuged at 175,000g for 24 hours to form a density gradient. Samples of different densities were collected in sequence and step by step, and samples were taken for titer determination. The fractions enriched with AAV particles were collected. Finally, the virus solution obtained by density gradient centrifugation was added to an ultrafiltration device for desalting, and PBS was added to a total volume of 4 mL. Centrifugation was performed at 1,500 × g for approximately 5 to 10 minutes, and the residual volume was checked every 5 minutes until the final volume was approximately 200 μL.

[0092] Through the steps of AAV virus packaging, concentration, purification, and ultrafiltration desalting, we obtained PHP.eB serotype virus assembled with AAV-Lec and control AAV-EGFP vectors.

[0093] 2. How does AAV-Lec-mediated immunotherapy work? Figure 4 As shown. Using tail vein injection, we injected 4×10 11 vg dose of virus to 6-month-old APP / PS1 mice.

[0094] After 4 weeks of administration, we found that red fluorescence of Flag was detected in both the cerebral cortex and hippocampus, indicating that AAV-Lec was able to cross the blood-brain barrier and effectively express antibodies in the infected brain tissue, see Figure 5 .

[0095] 3. To evaluate the efficacy of AAV-mediated antibody therapy, we injected AAV-Lec or control AAV-EGFP virus into 6-month-old male APP / PS1 mice or 3-month-old female APP / PS1 mice via tail vein intravenous injection. One month after virus injection, 7-month-old male APP / PS1 mice and female APP / PS1 mice were subjected to water maze behavioral tests to evaluate their cognitive and learning behaviors. The experimental route was as follows Figure 6 Given that sex differences in the behavior of AD mice have been reported, both male and female APP / PS1 mice were included in this study.

[0096] Thioflavin-S staining was used to analyze Aβ plaques in the cerebral cortex and hippocampus, and it was found that the number and total area of ​​Aβ plaques were greatly reduced after AAV-Lec administration compared with the AAV-EGFP group, with 100-500 μm 2 The number of Aβ plaques was significantly reduced. Figure 7-9 .

[0097] In the water maze test, AAV-Lec-treated APP / PS1 mice had a shorter latency to reach the target box during the training phase compared with the AAV-EGFP group. In addition, AAV-Lec-treated mice stayed in the target box longer and crossed the probe more times in the exploration trial, as shown in Figure 2. Fig.10 This showed that the mice's learning and memory abilities were significantly enhanced.

[0098] Example 3: AAV-Lec can reduce the activation of microglia and astrocytes in APP / PS1 mice

[0099] Because Aβ accumulation in APP / PS1 mice leads to abnormal activation of microglia and astrocytes, we investigated whether AAV-Lec treatment would reduce microglia and astrocyte activation.

[0100] After tail vein injection of AAV-Lec, the area of ​​Aβ plaques was significantly reduced, and the area of ​​activated microglia and astrocytes was significantly decreased, as shown in Figure 2. Fig.11 .

[0101] The results showed that AAV-Lec treatment led to a simultaneous reduction in Aβ accumulation and activation of astrocytes and microglia.

[0102] Example 4: AAV-Lec can reduce Aβ accumulation in 5×FAD mice

[0103] To further evaluate the efficacy of AAV-Lec, we also conducted similar studies in the 5×FAD AD mouse model using the same method as in Example 2.

[0104] After using AAV-Lec virus, thioflavin-T staining showed that the number and total area of ​​Aβ plaques in the cerebral cortex and hippocampus were significantly reduced. Fig.12 .

[0105] The results showed that AAV-Lec treatment could ameliorate the pathological symptoms of 5×FAD and APP / PS1 AD mouse models.

[0106] Example 5: Safety evaluation of AAV-Lec-mediated immunotherapy

[0107] Long-term expression of antibodies in the brain or other tissues may lead to inflammatory responses. Therefore, we evaluated the safety of the developed immunotherapy and examined inflammatory or pathological changes in the relevant tissues.

[0108] 1. Six-month-old male APP / PS1 mice or three-month-old female APP / PS1 mice were injected with AAV-Lec or control AAV-EGFP virus via tail vein intravenous injection. Four weeks after virus injection, the brain of the mice was examined for microbleeds using Prussian blue staining, and the liver tissue was examined using HE staining.

[0109] The results of Prussian blue staining showed that compared with the wild type, the brain tissues of the AAV-Lec treatment group and the AAV-EGFP control group did not show cerebral amyloid angiopathy (CAA) and microbleeding. Fig.13 .

[0110] The results of HE staining of liver tissue showed that compared with the wild type, there was no obvious pathological change or inflammation in the liver tissue of the AAV-Lec treatment group and the AAV-EGFP control group, as shown in Fig.14 .

[0111] Therefore, expressing Lec in the CNS did not induce brain microbleeds or liver inflammation, suggesting that AAV-mediated immunotherapy is safe.

[0112] 2. To further evaluate the safety of AAV-Lec-mediated immunotherapy, we performed transcriptome sequencing on the livers of APP / PS1 mice in the AAV-EGFP control group and the AAV-Lec treatment group.

[0113] The transcriptome results identified 33 significantly up-regulated genes and 56 significantly down-regulated genes, among which the significantly down-regulated genes were mainly related to lipid metabolism, such as Hmgcr, Msmo1, Mvk, Lss and Fdps, see Fig.15 .

[0114] Heat map analysis of these 12 lipid metabolism-related genes showed that the lipid metabolism-related genes in the liver of APP / PS1 mice in the AAV-Lec treatment group were significantly downregulated compared with those in the AAV-EGFP control group, indicating that AAV-Lec treatment played a role in alleviating abnormal lipid metabolism. Fig.16 .

[0115] At the same time, KEGG pathway enrichment analysis was performed, and the top 10 enriched pathways were Steroid biosynthesis, Terpenoid backbone Biosynthesis, African trypanosomiasis, Malaria, Signaling pathways regulating pluripotency of stem cells, Bile secretion, Maturity onset diabetes of the young, Chemical carcinogenesis-DNA adducts, AMPK signaling pathway, Glutathione metabolism, see Fig.17 .

[0116] 3. In order to verify that AAV-Lec treatment can alleviate abnormal lipid metabolism, we further designed three pairs of primers for genes related to lipid metabolism, Hmgcr, Fdps, and Hmgcs1, and performed qPCR using cDNA of liver and brain tissues of APP / PS1 mice in the AAV-EGFP control group and the AAV-Lec treatment group as templates.

[0117] The experimental results showed that compared with the AAV-EGFP control group, the mRNA expression of lipid metabolism-related genes in the brain and liver of APP / PS1 mice treated with AAV-Lec was significantly downregulated. Fig.18 This result is consistent with the sequencing result.

[0118] The above results indicate that AAV-Lec-mediated immunotherapy not only does not cause toxic side effects such as brain microbleeds or liver inflammation, but also can improve lipid metabolism function caused by AD.

Claims

1. A recombinant adeno-associated virus AAV-Lec, characterized in that: The AAV-Lec is an adeno-associated virus that expresses anti-Aβ antibodies, which are formed by a fusion protein consisting of a signal peptide for guiding protein secretion to the extracellular space, a light chain variable region and a heavy chain variable region of lencanerumab connected by a flexible connecting peptide, and an IgG constant region Fc segment.

2. The recombinant adeno-associated virus AAV-Lec according to claim 1, characterized in that The amino acid sequence of the signal peptide is shown in SEQ ID NO.

1.

3. The recombinant adeno-associated virus AAV-Lec according to claim 1, characterized in that The amino acid sequences of the light chain variable region and the heavy chain variable region of the lencanezumab are shown in SEQ ID NO.2 and SEQ ID NO.3, respectively; the amino acid sequence of the flexible connecting peptide is shown in SEQ ID NO.

4.

4. The recombinant adeno-associated virus AAV-Lec according to claim 1, characterized in that The amino acid sequence of the IgG constant region Fc segment is shown in SEQ ID NO.

5.

5. The recombinant adeno-associated virus AAV-Lec according to claim 1, characterized in that The AAV-Lec contains an anti-Aβ antibody gene expression frame, and the coding gene of the anti-Aβ antibody is composed of a start codon, a signal peptide coding sequence, a light chain variable region coding sequence, a flexible connecting peptide coding sequence, a heavy chain variable region coding sequence, an IgG constant region Fc segment coding sequence, and a stop codon in sequence. The coding sequences of the signal peptide, light chain variable region, flexible connecting peptide, heavy chain variable region, and IgG constant region Fc segment are shown in SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, and SEQ ID NO.10, respectively.

6. The recombinant adeno-associated virus AAV-Lec according to claim 5, characterized in that The promoter in the anti-Aβ antibody gene expression frame adopts the EF1A promoter.

7. The method for preparing the recombinant adeno-associated virus AAV-Lec according to any one of claims 1 to 6, characterized in that: include: The adeno-associated virus vector system plasmid is transfected into 293T cells, and the cell culture supernatant is collected on time after cultivation, concentrated and mixed with the cell lysis supernatant at night, and purified and desalted to obtain the recombinant adeno-associated virus AAV-Lec; the adeno-associated virus vector system plasmid includes a transfer plasmid containing an anti-Aβ antibody gene expression frame, an expression plasmid encoding replication and capsid proteins, and a helper plasmid Helper, and the three are transfected at a ratio of 1:1:

4.

8. The method for preparing the recombinant adeno-associated virus AAV-Lec according to claim 7, characterized in that: The serotype of the adeno-associated virus is selected from: AAV9, AAV-PHP.A, AAV-PHP.B, AAV.PHP.eB, AAV.BI-hTFR1, and AAV-AS.

9. Use of the recombinant adeno-associated virus AAV-Lec according to any one of claims 1 to 6 in the preparation of a drug for treating and preventing Alzheimer's disease or a drug for alleviating abnormal lipid metabolism caused by Alzheimer's disease, characterized in that: The drug can cross the blood-brain barrier and express anti-Aβ antibodies in the central nervous system through intravenous injection.

10. A recombinant adeno-associated virus AAV-Lec preparation, characterized in that: The preparation comprises the recombinant adeno-associated virus AAV-Lec as described in any one of claims 1 to 6 and a pharmaceutically acceptable carrier.